[go: up one dir, main page]

WO2009078432A1 - Composé 1-alkyl-4-amino-1h-pyrazole-3-carboxamide - Google Patents

Composé 1-alkyl-4-amino-1h-pyrazole-3-carboxamide Download PDF

Info

Publication number
WO2009078432A1
WO2009078432A1 PCT/JP2008/072965 JP2008072965W WO2009078432A1 WO 2009078432 A1 WO2009078432 A1 WO 2009078432A1 JP 2008072965 W JP2008072965 W JP 2008072965W WO 2009078432 A1 WO2009078432 A1 WO 2009078432A1
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
pharmaceutically acceptable
acceptable salt
pyrazole
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/072965
Other languages
English (en)
Japanese (ja)
Inventor
Kosuke Kanuma
Tomoko Tamita
Koreaki Imura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of WO2009078432A1 publication Critical patent/WO2009078432A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé 1-alkyl-4-amino-1H-pyrazole-3-carboxamide représenté par la formule (I) ou un de ses sels pharmaceutiquement acceptables. Le composé ou son sel pharmaceutiquement acceptable est utile en tant qu'agent médicinal ayant une activité antagoniste sur le récepteur du glutamate métabotropique de type 5. Le composé ou son sel pharmaceutiquement acceptable est utile pour la prévention ou le traitement de maladies comprenant les troubles de l'anxiété, les troubles de l'humeur, la schizophrénie, la douleur, la maladie de Parkinson, la maladie d'Alzheimer, le dysfonctionnement cognitif, les troubles de la mémoire, la démence, l'épilepsie, les troubles du sommeil, la pharmacodépendance, l'obésité, les troubles de l'appétit et de l'alimentation, les troubles gastro-intestinaux fonctionnels (FGID), les maladies urologiques et les maladies génitales.
PCT/JP2008/072965 2007-12-18 2008-12-17 Composé 1-alkyl-4-amino-1h-pyrazole-3-carboxamide Ceased WO2009078432A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-326496 2007-12-18
JP2007326496 2007-12-18

Publications (1)

Publication Number Publication Date
WO2009078432A1 true WO2009078432A1 (fr) 2009-06-25

Family

ID=40795546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072965 Ceased WO2009078432A1 (fr) 2007-12-18 2008-12-17 Composé 1-alkyl-4-amino-1h-pyrazole-3-carboxamide

Country Status (1)

Country Link
WO (1) WO2009078432A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020820A1 (fr) * 2010-08-11 2012-02-16 大正製薬株式会社 Dérivé d'hétéroaryl pyrazole
WO2012099200A1 (fr) * 2011-01-21 2012-07-26 大正製薬株式会社 Dérivé de pyrazole
CN105111260A (zh) * 2015-09-07 2015-12-02 淮海工学院 含氨基葡萄糖1,3,4-噻二唑衍生物及其制备方法与用途
CN105503977A (zh) * 2016-01-27 2016-04-20 淮海工学院 含氨基葡萄糖分子的1,3,4-噁二唑衍生物及其制备方法与用途
US9550792B2 (en) 2013-01-08 2017-01-24 Shanghai Fosun Pharmaceutical Development Co., Ltd. Polycyclic substituted pyrazole kinase activity inhibitors and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030128A2 (fr) * 2003-09-23 2005-04-07 Merck & Co., Inc. Modulateurs pyrazole de recepteurs de glutamate metabotropiques
WO2005079802A1 (fr) * 2004-02-12 2005-09-01 Merck & Co., Inc. Amides bipyridyles en tant que modulateurs du récepteur-5 métabotropique du glutamate
WO2006074884A1 (fr) * 2005-01-14 2006-07-20 F.Hoffmann-La Roche Ag Derives de thiazole-4-carboxamide en tant qu'antagonistes du mglur5
WO2006094639A1 (fr) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Dérivés de pyridine-2-carboxamide en tant qu’antagonistes du mglur5
WO2006094691A1 (fr) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Dérivés de pyrazine-2-carboxamide en tant qu’antagonistes du mglur5

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030128A2 (fr) * 2003-09-23 2005-04-07 Merck & Co., Inc. Modulateurs pyrazole de recepteurs de glutamate metabotropiques
WO2005079802A1 (fr) * 2004-02-12 2005-09-01 Merck & Co., Inc. Amides bipyridyles en tant que modulateurs du récepteur-5 métabotropique du glutamate
WO2006074884A1 (fr) * 2005-01-14 2006-07-20 F.Hoffmann-La Roche Ag Derives de thiazole-4-carboxamide en tant qu'antagonistes du mglur5
WO2006094639A1 (fr) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Dérivés de pyridine-2-carboxamide en tant qu’antagonistes du mglur5
WO2006094691A1 (fr) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Dérivés de pyrazine-2-carboxamide en tant qu’antagonistes du mglur5

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020820A1 (fr) * 2010-08-11 2012-02-16 大正製薬株式会社 Dérivé d'hétéroaryl pyrazole
WO2012099200A1 (fr) * 2011-01-21 2012-07-26 大正製薬株式会社 Dérivé de pyrazole
US9550792B2 (en) 2013-01-08 2017-01-24 Shanghai Fosun Pharmaceutical Development Co., Ltd. Polycyclic substituted pyrazole kinase activity inhibitors and use thereof
CN105111260A (zh) * 2015-09-07 2015-12-02 淮海工学院 含氨基葡萄糖1,3,4-噻二唑衍生物及其制备方法与用途
CN105111260B (zh) * 2015-09-07 2018-08-24 淮海工学院 含氨基葡萄糖1,3,4-噻二唑衍生物及其制备方法与用途
CN105503977A (zh) * 2016-01-27 2016-04-20 淮海工学院 含氨基葡萄糖分子的1,3,4-噁二唑衍生物及其制备方法与用途

Similar Documents

Publication Publication Date Title
PH12013501206A1 (en) Pyrazole derivative
JP2007502287A5 (fr)
PA8534801A1 (es) Derivados de piperazina
MX2011011489A (es) Derivados de isoxazol-piridina.
WO2005079802A8 (fr) Amides bipyridyles en tant que modulateurs du récepteur-5 métabotropique du glutamate
WO2008107480A8 (fr) Dérivés de 3-cyano-pyridone 1,4 disubstitués et leur utilisation comme modulateurs positifs des récepteurs mglur2
WO2006014918A3 (fr) Potentialisateurs d'acetophenone heterocycliques de recepteurs metabotropiques du glutamate
WO2004087116A3 (fr) Combinaison de medicaments pour le dysfonctionnement moteur dans la maladie de parkinson
MX2011011273A (es) Derivados de isoxazol-pirazol.
MX2011011477A (es) Derivados de isoxazol-piridazina.
WO2009078432A1 (fr) Composé 1-alkyl-4-amino-1h-pyrazole-3-carboxamide
DE602007001893D1 (en) Aryl-4-ethinylisoxazolderivate
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
WO2006047237A3 (fr) Potentialisateurs indanone heterocycliques des recepteurs metabotropiques du glutamate
WO2009017236A1 (fr) Dérivés de pyridopyrimidine-4-one
WO2005089753A3 (fr) Benzisoxazoles
MX2007005306A (es) Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
TW200745135A (en) Therapeutic agents
MX2009014001A (es) Derivados de isoxazol-imidazol.
MX2011008336A (es) Derivados de dihidroquinolinona.
IL198072A0 (en) Substituted pyrazinone derivatives for use as a medicine
PH12012501917A1 (en) Phenylpyrazole derivatives
MX2011011490A (es) Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
WO2007135131A8 (fr) Dérivés de pyrazinone substitués à utiliser comme médicament
TW200635589A (en) Therapeutic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08862879

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08862879

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP